CD40L activation in circulating platelets in patients with acute coronary syndrome

Cardiology

Volumn 92, Issue 1, 1999, Pages 11-16

  Lee, Yoon ^a   Lee, Won Ha ^b   Lee, Sang Chol ^a   Ahn, Kyoung Ju ^a   Choi, Yoon Ho ^a   Park, Seung Woo ^a,b   Lee, Sang Hoon ^a,b   Seo, Jung Don ^a,b   Park, Jeong Euy ^a,b,c  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Acute coronary syndrome; Atherosclerosis; CD40L; Platelets

Indexed keywords

CD31 ANTIGEN; CD40 ANTIGEN; GLYCOPROTEIN GP 39;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MACROPHAGE; MALE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

EID: 0033371183     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006940     Document Type: Article

References (21)

1. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ: Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996;14: 591-617.
2. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
3. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997;94:1931-1936.
4. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA, Aruffo A: Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995;182:33-40.
5. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, Nadler LM: Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989; 169:2043-2058.
6. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK: CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993;178:669-674.
7. Laman JD, de Smet BJ, Schoneveld A, van Meurs M: CD40-CD40L interactions in atherosclerosis. Immunol Today 1997;18:272-277.
8. Mach F, Schonbeck U, Bonnefoy JY, Pober JS. Libby P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399.
9. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-454.
10. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200-203.
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318.
12. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362: 801-809.
13. Jackson AL, Waener NL: Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes: in Rose NR, Freidman H, Fahey JL (eds): Manual of Clinical Laboratory Immunology, ed 3. Washington, American Society for Microbiology 1986, pp 226-235.
14. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis HK, Roos D, de Korte D: Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion 1990;30:20-25.
15. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SBd, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL, Jr, et al: Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486-502.
16. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-936.
17. Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156:3952-3960.
18. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM: Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994;269:22027-22033.
19. Serebruany VL, Gurbel PA: Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction [In Process Citation]. Arterioseler Thromb Vasc Biol 1999; 19:153-158.
20. Serebruany VL, Bahr RD, O'Connor CM, Lowry DR, Gurbel PA: Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. Cardiology 1998;90:37-42.
21. Knight CJ, Panesar M, Wilson DJ, Chronos NA, Patel D, Fox K, Goodall AH: Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997;95:125-132.